dimethyl fumarate controlled release (FP 187) / Forward Pharma - LARVOL DELTA

Forward Pharma Reports second quarter 2015 financial and operational results (GlobeNewswire) - "Research and development expenses were $10 million for the quarter ended June 30, 2015 compared to $2.5 million for the same period in 2014...continue to expect our quarterly rate of research and development spend will increase in the future as we prepare for the FP187 Phase 3 relapsing-remitting multiple sclerosis (RRMS) trial..."

Anticipated new P3 trial • Commercial • Multiple Sclerosis

FP-187: Patent expiry in US in 2029 (Forward Pharma) - Annual Report: Patent protection in Europe until October 2025; Patent expiry related to erosion matrix in US in January 2030

Patent • Psoriasis